These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1257 related articles for article (PubMed ID: 24076235)

  • 1. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.
    Sharifzadeh Z; Rahbarizadeh F; Shokrgozar MA; Ahmadvand D; Mahboudi F; Jamnani FR; Moghimi SM
    Cancer Lett; 2013 Jul; 334(2):237-44. PubMed ID: 22902507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization.
    Hanssens H; Meeus F; De Vlaeminck Y; Lecocq Q; Puttemans J; Debie P; De Groof TWM; Goyvaerts C; De Veirman K; Breckpot K; Devoogdt N
    Front Immunol; 2024; 15():1389018. PubMed ID: 38720898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
    Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advances in immunotherapy of hematological malignancies by using chimeric antigen receptor-modified lymphocytes].
    Xu XJ; Zhao HZ; Tang YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):521-5. PubMed ID: 23628068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
    Hombach A; Hombach AA; Abken H
    Gene Ther; 2010 Oct; 17(10):1206-13. PubMed ID: 20555360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells.
    Rajabzadeh A; Rahbarizadeh F; Ahmadvand D; Kabir Salmani M; Hamidieh AA
    Cell J; 2021 Jan; 22(4):502-513. PubMed ID: 32347044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
    Textor A; Listopad JJ; Wührmann LL; Perez C; Kruschinski A; Chmielewski M; Abken H; Blankenstein T; Charo J
    Cancer Res; 2014 Dec; 74(23):6796-805. PubMed ID: 25297631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
    Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
    Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
    Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
    J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
    Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
    IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 14. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.
    Nakazawa Y; Huye LE; Salsman VS; Leen AM; Ahmed N; Rollins L; Dotti G; Gottschalk SM; Wilson MH; Rooney CM
    Mol Ther; 2011 Dec; 19(12):2133-43. PubMed ID: 21772253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
    Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
    Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
    J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.
    Hombach AA; Abken H
    Int J Cancer; 2011 Dec; 129(12):2935-44. PubMed ID: 22030616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: In vitro proof-of-concept.
    Khoshtinat Nikkhoi S; Rahbarizadeh F; Ahmadvand D; Moghimi SM
    Eur J Pharm Sci; 2018 Sep; 122():42-50. PubMed ID: 29933078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen.
    Shirasu N; Shibaguci H; Kuroki M; Yamada H; Kuroki M
    Anticancer Res; 2010 Jul; 30(7):2731-8. PubMed ID: 20683006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties.
    Hanssens H; Meeus F; Gesquiere EL; Puttemans J; De Vlaeminck Y; De Veirman K; Breckpot K; Devoogdt N
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.